Sanofi Pasteur

Discovery Drive
Swiftwater, PA 18370

Sanofi Pasteur News

Brazil approves Sanofi Pasteur's dengue vaccine

Sanofi Pasteur, Sanofi’s vaccines division, recently received regulatory approval from Brazil for the company’s dengue fever vaccine, called Dengaxia, which is designed to protect people from contracting dengue fever from infected mosquitoes. Read More »

Philippines officials approve Sanofi Pasteur vaccine for dengue

Philippines health officials on Tuesday granted approval for the vaccine Dengvaxia, manufactured by Sanofi Pasteur, for against dengue. Read More »

Mexican health officials approve Sanofi's dengue vaccine

Sanofi Pasteur’s Dengvaxia, the first dengue fever vaccine in the world, recently gained marketing authorization in Mexico. Read More »

Injectable polio vaccine available for infants in India

ShanIPV, an inactivated, injectable polio vaccine (IPV), will soon be accessible for infants in India. Read More »

Sanofi Pasteur shares universal influenza vaccine research

Representatives from Sanofi Pasteur, the vaccines division of Sanofi, recently gave a presentation about its new universal influenza vaccine at the World Vaccine Congress in Madrid. Read More »

Global center launches to develop products to stem infectious disease

Sanofi Pasteur, Sanofi’s vaccine division, recently announced that it has launched a Global Health Vaccine Center of Innovation (GHVCI) as part of its collaboration with the Infectious Disease Research Institute (IDRI), a nonprofit, global-health institute that specializes in creating new products for infectious diseases. Read More »

Economic analysis of higher-dose and standard-dose influenza vaccine for elderly

The Lancet Infectious Diseases recently published a new economic analysis comparing higher-dose influenza vaccines with standard-dose influenza vaccines among senior citizens. Read More »

Sanofi Pasteur delivers first 2015-2016 seasonal flu vaccines in U.S.

Sanofi Pasteur, the Sanofi vaccine division, recently announced the first shipment of its original Fluzone influenza vaccine doses for the upcoming 2015 and 2016 influenza season in the U.S. Read More »

European committee gives positive review to GARDASIL 9 HPV vaccine

New vaccine by Sanofi Pasteur MSD contains largest quantity of HPV types. Read More »

FDA approves Quadracel DTaP-IPV vaccine

Immunization protects children from poliomyelitis, pertussis, diphtheria and tetanus. Read More »

Shantha, Sanofi to provide 37 million immunizations worldwide

As part of an international tender that lasts two years, Sanofi Pasteur, a vaccine branch of Sanofi, recently announced that its partner Shantha Biotechnics has been awarded the opportunity to provide 37 million Shan5™ doses to worldwide health organizations. Read More »

Hexyon gains European Commission grant for 2+1 immunization schedule

The European Commission recently gave Sanofi Pasteur MSD permission for a new vaccination schedule of 2+1 doses for Hexyon®, a novel 6-in-1 pediatric DTaP-IPC-HB-Hib vaccine. The decision to approve the new 2+1 schedule calls for 2 doses and then 1 booster vaccine. Read More »

FDA approves adult Fluzone Intradermal Quadrivalent flu vaccine

The U.S. Food and Drug Administration (FDA) approved Sanofi Pasteur's application for a Fluzone Intradermal Quadrivalent vaccine supplemental biologics license on Friday. Read More »

FDA approves Sanofi Pasteur’s supplemental biologics license

The United States Food and Drug Administration (FDA) recently approved a supplemental biologics license application for Sanofi Pasteur’s new Fluzone® High-Dose influenza vaccine. Read More »

Positive results from study of dengue fever vaccine

The data from the final phase III of a dengue fever vaccine developed by Sanofi Pasteur has been released. Read More »

FDA approves new prescribing information for Fluzone High-Dose flu vaccine

The U.S. Food and Drug Administration recently approved Sanofi Pasteur’s request to include data in the prescribing information for its Fluzone High-Dose flu vaccine that shows it is more effective in protecting older patients. Read More »